PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designation Advancing Ketamine and…
Month: June 2021
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) — – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the…
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) — – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the…
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage…
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage…
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
Recruitment ongoing in Europe Primary objectives: to assess the effect of vafidemstat to address agitation…
ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
Recruitment ongoing in Europe Primary objectives: to assess the effect of vafidemstat to address agitation…
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round
Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support…
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round
Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support…
Longeveron to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
MIAMI, June 15, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical…
Longeveron to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
MIAMI, June 15, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical…
QOMPLX Expands “Privilege Assurance: Graph View” Visualizing Your Vulnerabilities and Enabling Rapid Response
See your Active Directory the way a hacker does — before you become a target…
Reflect Scientific Now Fully Reporting Issuer With SEC
OREM, Utah, June 15, 2021 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider…
Reflect Scientific Now Fully Reporting Issuer With SEC
OREM, Utah, June 15, 2021 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider…
Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates
Virtual event will take place on June 21, 2021 from 1:00 – 2:30 p.m. ET…
Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates
Virtual event will take place on June 21, 2021 from 1:00 – 2:30 p.m. ET…
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both…
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both…